Publication

EULAR •
12 June, 2024 •
•

Long-term improvements in serum uric acid levels, gout symptoms, and safety up to 12-months with SEL-212 in gout refractory to conventional therapy: Results from the DISSOLVE I Phase 3, double-blind, placebo-controlled clinical trial

Alan Kivitz, Atul Singhal, Anand Patel, Kwabena Ayesu , Joanna Sobierska, Hugues Santin-Janin, Wesley DeHaan, Rehan Azeem, Peter Traber, Herbert Baraf

Available materials

Poster

Publication

EULAR •
12 June, 2024 •
•

Once-monthly SEL-212 demonstrates efficacy and safety for up to 6-months in gout refractory to conventional therapy: Combined data from the DISSOLVE I & II Phase 3, double-blind, placebo-controlled clinical trials

Herbert Baraf, Puja Khanna, Anand Patel, Atul Singhal, Joanna Sobierska, Hugues Santin-Janin, Rehan Azeem, Wesley DeHaan, Peter Traber, Alan Kivitz

Available materials

Poster

Publication

ASN •
6 November, 2025 •
•

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Minesh Rajpal, Vibeke Strand, Rehan Azeem, Ben Peace, Bhavisha Desai, Richard J. Johnson

Publication

ASN •
6 November, 2025 •
•

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients with Uncontrolled Gout (UG) and Stage 3 CKD

Health-related quality of life (HRQoL) and other secondary clinical outcomes in adults with gout refractory to conventional therapy treated with SEL-212: Pooled 6-month data from the phase 3 DISSOLVE I & II clinical trials

Long-term improvements in serum uric acid levels, gout symptoms, and safety up to 12-months with SEL-212 in gout refractory to conventional therapy: Results from the DISSOLVE I Phase 3, double-blind, placebo-controlled clinical trial

Once-monthly SEL-212 demonstrates efficacy and safety for up to 6-months in gout refractory to conventional therapy: Combined data from the DISSOLVE I & II Phase 3, double-blind, placebo-controlled clinical trials

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients with Uncontrolled Gout (UG) and Stage 3 CKD

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists